Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term drisapersen in Duchenne muscular dystrophy
NL-OMON43602Phase 3Withdrawn
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jul 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of drisapersen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Long-term safety and tolerability of drisapersen. Planned start Jul 2015; status: withdrawn.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON43602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43602.